Short Interest in Dynavax Technologies Co. (NASDAQ:DVAX) Grows By 6.0%

Dynavax Technologies Co. (NASDAQ:DVAXGet Free Report) was the recipient of a large growth in short interest in March. As of March 15th, there was short interest totalling 17,350,000 shares, a growth of 6.0% from the February 29th total of 16,370,000 shares. Based on an average trading volume of 1,960,000 shares, the days-to-cover ratio is presently 8.9 days.

Dynavax Technologies Trading Down 0.4 %

Shares of NASDAQ DVAX traded down $0.05 during mid-day trading on Wednesday, hitting $12.26. 109,953 shares of the company were exchanged, compared to its average volume of 1,976,385. The stock has a 50 day simple moving average of $12.66 and a 200-day simple moving average of $13.49. Dynavax Technologies has a 1-year low of $9.73 and a 1-year high of $15.15. The company has a debt-to-equity ratio of 0.41, a current ratio of 13.81 and a quick ratio of 12.96.

Wall Street Analyst Weigh In

Several analysts recently commented on DVAX shares. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Wednesday, March 6th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 23rd. Finally, The Goldman Sachs Group began coverage on shares of Dynavax Technologies in a research note on Thursday, February 1st. They set a “neutral” rating and a $20.00 target price for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $25.00.

View Our Latest Analysis on DVAX

Insider Buying and Selling

In other news, CAO Justin Burgess sold 20,526 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $12.78, for a total value of $262,322.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 9.31% of the stock is owned by company insiders.

Hedge Funds Weigh In On Dynavax Technologies

A number of large investors have recently bought and sold shares of the company. Advisors Asset Management Inc. increased its stake in shares of Dynavax Technologies by 498.0% during the first quarter. Advisors Asset Management Inc. now owns 2,362 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 1,967 shares during the period. Quantbot Technologies LP increased its position in Dynavax Technologies by 940.7% during the 1st quarter. Quantbot Technologies LP now owns 2,508 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 2,267 shares during the period. BluePath Capital Management LLC acquired a new position in Dynavax Technologies during the 3rd quarter worth approximately $33,000. DekaBank Deutsche Girozentrale purchased a new position in shares of Dynavax Technologies during the 3rd quarter worth approximately $33,000. Finally, Bartlett & CO. Wealth Management LLC acquired a new stake in shares of Dynavax Technologies in the 4th quarter valued at approximately $50,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

About Dynavax Technologies

(Get Free Report)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

See Also

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.